Immune Design Corp. (NASDAQ:IMDZ)’s share price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $6.43 and last traded at $6.53, with a volume of 232,094 shares. The stock had previously closed at $7.01.

IMDZ has been the topic of several recent analyst reports. Wells Fargo & Co. reissued a “buy” rating on shares of Immune Design Corp. in a report on Wednesday, May 11th. Leerink Swann reissued a “buy” rating on shares of Immune Design Corp. in a report on Friday, June 10th. Zacks Investment Research cut Immune Design Corp. from a “buy” rating to a “hold” rating in a report on Friday, May 13th. Cowen and Company reissued a “buy” rating on shares of Immune Design Corp. in a report on Wednesday, May 11th. Finally, Jefferies Group reissued a “buy” rating and set a $20.00 target price on shares of Immune Design Corp. in a report on Wednesday, May 11th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $24.00.

The stock’s 50-day moving average is $9.37 and its 200-day moving average is $11.67. The company’s market cap is $139.46 million.

Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.01. Equities analysts forecast that Immune Design Corp. will post ($2.70) EPS for the current fiscal year.

A number of hedge funds and institutional investors have bought and sold shares of the company. Oxford Asset Management acquired a new position in Immune Design Corp. during the fourth quarter valued at about $1,166,000. Jennison Associates raised its position in Immune Design Corp. by 0.6% in the third quarter. Jennison Associates now owns 202,683 shares of the company’s stock valued at $2,473,000 after buying an additional 1,224 shares during the period. Finally, Jennison Associates LLC raised its position in Immune Design Corp. by 0.4% in the fourth quarter. Jennison Associates LLC now owns 203,452 shares of the company’s stock valued at $4,085,000 after buying an additional 769 shares during the period.

Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.